Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer

Weniger, Maximilian; Moir, John; Damm, Marko; Maggino, Laura; Kordes, Maximilian; Rosendahl, Jonas; Ceyhan, GÜRALP; Schorn, Stephan

doi:10.1016/j.pan.2020.06.012

Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer

Weniger M., Moir J., Damm M., Maggino L., Kordes M., Rosendahl J., ...Daha Fazla

PANCREATOLOGY, cilt.20, sa.6, ss.1131-1138, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 20 Sayı: 6
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.pan.2020.06.012
Dergi Adı: PANCREATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.1131-1138
Anahtar Kelimeler: FOLFIRINOX, Gemcitabine, Nab-paclitaxel, Neoadjuvant chemotherapy, ADJUVANT CHEMOTHERAPY, OPEN-LABEL, GEMCITABINE, FOLFIRINOX, RESECTION, ADENOCARCINOMA, PHASE-3, DEATHS
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background: Neoadjuvant chemotherapy has become a powerful tool to convert borderline resectable (BRPC) and locally advanced pancreatic cancers (LAPC) into a resectable scenario. However, data analyzing the optimal type of therapy are scarce. In the present multicenter retrospective study, we evaluated the influence of FOLFIRINOX (FFX) and gemcitabine (GEM)-based neoadjuvant therapy on patient prognosis.